Antimicrobial Resistance as a Silent Pandemic: Ecological, Genetic, and One Health Drivers of Global Treatment Failure

From Miracle Drugs to a Global Emergency

The discovery and clinical application of antibiotics represented one of the most profound breakthroughs in the medical history that changed the survival rate of bacterial infections and made possible surgeries, organ transplants, cancer chemotherapy, and intensive care medicine.¹ It is well, recorded that the antibiotic era brought about significant mortality reductions, but along with it came a major evolutionary paradox: basically, bacteria started to develop resistance from the very first moment antibiotics were used, through mutation, selection, and horizontal gene transfer, thus embedding resistance as a biological response of bacteria to antimicrobial pressure.¹ Over the next several decades, the massive use of antibiotics in humans, animals, and farms has created an unprecedented selective pressure that has accelerated the rise and global spread of resistant organisms among human, animal, and environmental interconnected reservoirs.^2,4 According to the World Health Organizations (WHO) surveillance data, antimicrobial resistance (AMR) is now widespread globally and across all major groups of pathogens, resulting in the treatment of common infections becoming less effective and healthcare delivery being threatened at its very core.^5,6 This rising threat has turned antibiotics from miracle drugs into extremely attractive tools that hardly deliver their purpose, thereby signalling a shift from the medical victory to a global public health disaster.^7,8

Historical Evolution of Antibiotics

The history of antibiotics has been characterized by a cycle of discovery, usage, and resistance, from early antibiotics like penicillin to recent broad-spectrum therapies.¹ Each new antibiotic class initially provided benefits, but resistance emerged as bacteria found ways to escape drug effects through mutations and gene acquisition.^1,4 Bacteria now become resistant faster than new antibiotics are discovered, leading to fewer effective drugs against multidrug-resistant pathogens.⁷ Global monitoring shows resistance affects infections across worldwide communities, regardless of development level.⁶ Resistance results from antimicrobial overuse, and the long-standing imbalance between antimicrobial development and microbial evolution has made it an inherent characteristic of modern medicine.^1,9

How Misuse Transformed Life-Saving Drugs into a Global Threat

The situation of antibiotics from being a saving, life intervention to a cause of resistance, related global crisis has been mainly because of their misuse, overuse, and poorly regulated distribution in health systems and food production supply chains.^{10, 2} On the other hand, systematic research has shown that antimicrobial stewardship programs can significantly reduce the unnecessary use of antibiotics; however, their application is still very uneven around the world, and inappropriate prescribing still continues to occur on a large scale.¹⁰ In low, and middle, income countries, misuse and resistance transmission between humans, animals, and the environment are further exacerbated by weak regulatory frameworks, limited diagnostics, and fragmented healthcare, which makes it easier for resistance to be transmitted.² Environmental research has also shown that antibiotics and resistance genes are now deeply associated with aquatic ecosystems, rivers, estuaries, and coastal marine environments, thus creating natural reservoirs that help and even increase the spread of resistance not only in clinical settings but also at the community level and beyond.³ At the same time, the latest results from the ongoing research about the role of micro, and nanoplastics in the environment suggest that these plastics could facilitate the rapid transfer of resistance genes between bacteria (a process known as horizontal gene transfer) thus posing a great risk as one of the environmental, to, human transmission routes that could become major in the near future.⁴ All these factors interconnecting to each other have turned the main ingredient in the therapy of diseases, namely antibiotics, into a worldwide ecological factor that continuously influences and reshapes the microbial evolution on earth.^{2, 4, 11}

Rationale for Addressing Antibiotic Resistance Now

The need to contain AMR cannot be overstated considering its increasing clinical, economic, and societal challenges. The most detailed worldwide study ever conducted suggests that bacterial AMR caused directly millions of deaths internationally between 1990 and 2021, and the prediction is that there will be more deaths by 2050 if the current trend continues.¹² Worldwide WHO surveillance data on the resistance of common bacterial pathogens without exception confirm the forecasts.^{5, 6} In addition to deaths, antibiotic resistance puts a lot of strain on the economy. Systematic reviews of the literature have shown that resistant infections are associated with significantly higher healthcare costs, longer hospital stays, and productivity losses compared to susceptible ones.¹³ Time, series analyses also show that rises in antibiotic consumption are followed by measurable increases in resistance among hospitalized patients, which means that the effects of prescribing behavior are delayed but expected.¹⁴ All these discoveries combined make it clear that if we do not take action, the result will be an ever, increasing loss of human lives and financial resources that will put at risk global healthcare systems.^{6, 12, 14}

Table 1. Global burden of antimicrobial resistance

The table presents the worldwide clinical and economic and equity-related effects of antimicrobial resistance (AMR) showing all associated deaths and disability-adjusted life years (DALYs) and healthcare expenditures and the greater effects observed in low- and middle-income countries who experience contemporary international and regional analysis.

Some emerging platforms (e.g., engineered bacteriophages) integrate multiple antimicrobial mechanisms, including direct bacterial killing and delivery of gene-editing systems, which explains overlapping citation across strategy categories.

10.1 Next-Generation Antibiotics & Novel Drug Targets

Modern antibiotic development is increasingly focused on novel bacterial targets, non-traditional chemical scaffolds, and resistance-evading mechanisms rather than rediscovery of existing drug classes. Miethke et al. emphasize that genomic mining, structure-guided design, and pathway-specific inhibitors are now being used to identify compounds that interfere with essential bacterial processes such as cell envelope assembly, energy metabolism, and virulence regulation, thereby reducing cross-resistance with existing antibiotics.⁸⁵ However, Butler et al. show that despite scientific advances, most agents in the current clinical pipeline still belong to known antibiotic families, making them vulnerable to pre-existing resistance mechanisms and limiting their long-term impact.⁸⁶ This imbalance highlights a critical gap between innovation in discovery platforms and actual therapeutic diversity reaching patients, reinforcing the urgency for drugs with genuinely new modes of action.^85,86

10.2 Phage Therapy: Reviving a Century-old Strategy

Bacteriophage therapy has re-emerged as a powerful precision tool against multidrug-resistant bacteria, offering host-specific killing without disrupting normal microbiota. Pirnay et al. describe the “magistral phage” approach, in which personalized phage preparations are manufactured for individual patients with otherwise untreatable infections, enabling rapid targeting of resistant pathogens^.88 This strategy was clinically validated by Dedrick et al., who successfully used engineered bacteriophages to treat a disseminated Mycobacterium abscessus infection resistant to all available antibiotics, demonstrating that phages can be genetically optimized to enhance lytic activity and therapeutic efficacy.⁸⁹ Yosef et al. further showed that bacteriophages can be programmed to selectively kill resistant bacteria or restore antibiotic susceptibility, allowing phages to function both as direct antimicrobials and as resistance-modifying agents.⁹⁰ Together, these studies establish phage therapy as a highly adaptable biological platform capable of addressing infections that conventional antibiotics can no longer control.^88-90

10.3 CRISPR-based Antimicrobials

CRISPR-Cas systems represent a new class of precision antimicrobials capable of eliminating bacteria or specific resistance genes at the DNA level. Pursey et al. explain that CRISPR-based antimicrobials can be designed to selectively target plasmids or chromosomal sequences encoding antibiotic resistance, enabling either bacterial killing or re-sensitization to existing drugs.⁹¹ Yosef et al. experimentally demonstrated this concept by engineering bacteriophages to deliver CRISPR systems that selectively destroy resistance genes, converting previously resistant bacteria into antibiotic-susceptible strains.⁹⁰ This dual-function strategy transforms CRISPR from a gene-editing tool into a programmable antimicrobial weapon, offering a fundamentally different way to manage resistance that bypasses traditional drug-target interactions.^91,90

10.4 Nanotechnology-enabled Antibacterial Agents

Nanotechnology offers a versatile platform for antimicrobial therapy through mechanisms that bacteria cannot easily evade. Wang et al. showed that metallic and polymeric nanoparticles exert antibacterial effects via membrane disruption, reactive oxygen species generation, and interference with intracellular processes, allowing them to kill even multidrug-resistant organisms.⁹² Unlike conventional antibiotics, nanoparticles have a distinct mechanism of action, and they do not depend on single molecular targets. Therefore, the probability of resistance development is significantly decreased, and nanoparticles can act against biofilms and even dormant bacterial populations.⁹² Their adjustable size, surface charge, and functionalization also permit targeted delivery and the use of antibiotics in a synergistic manner. This makes nanomaterials viable options not only as standalone antimicrobials but also as resistance, breaking adjuvants.⁹²

10.5 AI-Driven Drug Discovery and Diagnostic Prediction

Artificial intelligence (AI) has started to play a huge role in changing how new antimicrobials are discovered and how clinical decisions are made. Stokes and colleagues have shown that deep learning algorithms are able to pinpoint structurally novel antibiotics among huge chemical libraries, which resulted in the finding of compounds with strong activities against multidrug, resistant pathogens, whereas these compounds have not been found by traditional screening methods.⁹³ Topol, on the other hand, explains how in addition to drug discovery, AI systems are able to combine clinical, microbiological, and imaging data to provide more accurate diagnoses, predict the response to a given treatment, and hence, help in deciding on the ideal antimicrobial therapy for a particular patient, which, in turn, results in less antibiotic use and faster efficient treatments.⁹⁴ By putting together AI, based drug discovery and AI, supported clinical decision, making, a closed, loop system is created which not only churns out new antibiotics but also maximizes their use in real, life healthcare settings.^93,94

11. Antimicrobial Stewardship, Surveillance, and Regulatory Gaps

Antimicrobial resistance (AMR) emerges from two main factors which involve both microbial evolution and the improper implementation of stewardship and surveillance systems and regulatory frameworks that currently exist in healthcare settings. The established patterns of resistance together with the documented antimicrobial usage across different regions and clinical syndromes face challenges in achieving uniform implementation throughout medical practice.6 Surveillance data show that resistant pathogens exist in both community and hospital environments, yet national and institutional responses differ significantly in their scope and enforcement and their ability to maintain control.⁶ The existing technical frameworks fail to meet their intended purpose because organizations are unable to implement their necessary requirements.^6,8,98

11.1 Surveillance Systems Supporting Clinical Practice

Surveillance functions as the primary method which enables antimicrobial stewardship to link antimicrobial usage patterns with documented resistance trends. The World Health Organization's Global Antimicrobial Resistance and Use Surveillance System (GLASS) provides a framework which enables standardized resistance reporting for major pathogens across different clinical syndromes, thus allowing for comparison of resistance data between different locations and through various time periods.⁶ The value of surveillance in clinical settings exists because its information requires direct implementation in clinical decision processes instead of serving as an independent reporting system.⁸ Environmental and population-level monitoring methods which operate together with other techniques show that resistance factors exist in locations which extend beyond healthcare environments, thus demonstrating the need for surveillance systems which should operate outside hospital laboratory settings.⁵⁷ The data show that surveillance operates most effectively when it supports empirical therapy and local guidelines and early outbreak detection instead of functioning as a tool for backtracking policy decisions.^6,57

11.2 Antimicrobial Stewardship Across Care Settings

Antimicrobial stewardship functions as the most efficient method which accomplishes two goals by reducing incorrect antibiotic prescription practices and preventing the development of antibiotic resistance. The clinical evidence demonstrates that structured stewardship programs effectively decrease infections from both resistant pathogens and Clostridioides difficile by showing that doctors' prescribing choices directly affect resistance patterns.⁴⁴ The advantages of stewardship programs which include better patient outcomes and improved antibiotic use create a barrier for their implementation because hospitals fail to adopt these programs. The COVID-19 pandemic showed that doctors continued to prescribe antibiotics without confirming bacterial infections which created major challenges for doctors who needed to follow stewardship practices during uncertain clinical situations.^43,99 The evidence demonstrates that stewardship programs need to expand their reach from hospital environments to include primary healthcare settings and long-term care facilities and community medication prescribing which should receive educational support and accountability systems to establish long-term behavioural transformation.^44,99

11.3 Genomic and Environmental Surveillance for Resistance Detection

Genomic technology advancements now enable researchers to monitor antimicrobial resistance patterns with improved accuracy than before. Whole-genome sequencing provides essential information for healthcare institutions to determine how diseases spread, track resistance development, and identify disease outbreak sources.¹⁰⁰ Metagenomic analysis of urban sewage shows that resistance genes in the population correlate with community antibiotic consumption and spread through the population without depending on hospital data.⁵⁷ The combination of these methods with clinical surveillance results in a complete understanding of resistance development and spread, which leads to earlier detection of dangerous clones and guides specific preventive measures.^6,60,100

11.4 Regulatory and Economic Barriers to Sustainable Control

The existence of stewardship and surveillance frameworks fails to sustain their extended effectiveness because existing regulatory and economic restrictions keep undermining their operations. Antimicrobial regulations face weak enforcement in places with informal antibiotic markets which leads to ongoing improper usage of antibiotics despite existing treatment protocols.⁹⁸ The existing economic framework for antibiotic development hinders progress because stewardship-based practices decrease financial benefits which restrict innovation.98 The proposed reimbursement solutions use revenue models which disregard sales volume to solve the existing supply chain discrepancy while maintaining responsible usage practices.^100,101 The combination of stewardship targets and regulatory monitoring needs to establish sustainable drug development financial systems before hospitals can maintain their surveillance and prescription control achievements.^98,101

12. One Health Approach: Merging Human, Animal, and Environmental Health

Antimicrobial resistance (AMR) is now widely recognized as a quintessential One Health problem, arising from the continuous circulation of resistant bacteria and resistance genes across human, animal, and environmental systems rather than from isolated sectors.^28,102,47 Global policy frameworks from the World Health Organization and its quadripartite partners emphasize that antimicrobial use in humans, food-producing animals, and environmental contamination are biologically interconnected, such that selective pressure in one domain rapidly propagates into the others through food chains, water systems, direct contact, and microbial gene exchange.^103,104 Ecological and evolutionary analyses further demonstrate that resistance genes behave as mobile biological commodities that flow freely across species and ecosystems, making it impossible to control AMR within clinical settings alone.^102,58,59 Large-scale surveillance studies confirm this interconnectedness: faecal resistome profiling in European livestock reveals a high abundance and diversity of resistance genes that mirror those detected in human pathogens, demonstrating that agricultural reservoirs directly contribute to the broader resistome circulating in populations.¹⁰⁵ At the same time, worldwide surveillance of antimicrobial resistance in animals indicates that resistance levels are rising very quickly in low, and middle, income countries. This is mainly due to increased livestock production and use of antimicrobials in these countries, which constitute serious risks for public health that cut across sectors.⁵² Besides, environmental research reveals that antibiotic leftovers, resistant bacteria and resistance genes remain in the soil and water systems where they are constantly being chosen, increased and re, introduced in both animal and human populations, thus making AMR a natural disorder alongside a purely medical one.^58,59 The One Health framework explains how resistance develops because it shows the process of resistance creation together with its permanent nature which makes reversal efforts impossible. Hospitals experience decreased antibiotic use but resistance continues because agricultural methods and environmental reservoirs function as permanent systems which maintain and spread resistance genes.^47,59 Research demonstrates that food-producing animals create essential links within this system because livestock antibiotic treatment results in resistant bacteria which spread through meat and manure and agricultural runoff to cause rising resistance levels in both livestock and humans.^53,105,52 The issue becomes worse because environmental pollution allows antibiotic residues and resistance genes to remain in water and soil, which then enables environmental bacteria to transfer genes to human pathogens, resulting in the emergence of new strains that become resistant and cause medical infections.^58,59 The separate systems need to implement integrated management because any intervention in one area will fail due to ongoing selection and transmission in the other areas.^103,102,104 The integrated One Health strategies have shown that different sectors can work together to effectively reduce resistance through their unified efforts. The WHO Global Action Plan together with the One Health Joint Plan of Action requires countries to develop unified systems for monitoring antimicrobial usage through combined surveillance efforts which include both environmental protection and regulatory changes as well as antimicrobial stewardship practices to stop resistance from spreading through natural ecosystems while treating its health effects.^103,104 The systematic review evidence shows that when countries limit antimicrobial usage in food-producing animals it results in lower resistance rates among both animals and humans which demonstrates that agricultural stewardship acts as an effective method for safeguarding public health.⁵³ The national data from high-income countries proves the effectiveness of this method by showing that the Netherlands achieved substantial and permanent decreases in veterinary antimicrobial usage through their regulatory measures and industry cooperation and their monitoring efforts which maintained animal health and productivity levels.¹⁰⁶ The SWEDRES-SVARM integrated monitoring system in Sweden establishes that its coordinated approach to monitoring antibiotic sales and resistance patterns and veterinary activities enables healthcare professionals to identify new health risks early while maintaining low resistance rates in both the human and animal populations.¹⁰⁷ Even in Africa, low and middle, income countries such as Namibia and Nigeria are showing the practicability of a One Health governance system when there is a political will, and coordination across sectors is achieved. Public, animal, and environmental health sectors coming together to combat the emergence and spread of drug resistance infections and promote use of safe and efficacious medicines is a very powerful approach⁶³. Thailand’s national AMR strategy is a One Health approach which aligns human health, veterinary regulation, pharmaceutical governance, and public awareness under a single integrated framework, thus resulting in enhanced antimicrobial stewardship, stronger surveillance, and better alignment between/policy and practice.⁶³ Indeed, these various stories indicate that AMR is not simply an unavoidable consequence of human medicine or agriculture, but rather a manageable ecological and governance problem which can be solved through combined One Health systems that at the same time control antimicrobial use, keep track of resistance, and conserve environmental hygiene.^{28,102-104,59,106,107,63}

13. Future Directions: Translating Surveillance and AI into Clinical Practice

Improvements in the resolution of surveillance and data, driven decision support are gradually becoming the main factors directing future antimicrobial resistance (AMR) management rather than long, term predictive modelling. Nowadays, present, day surveillance systems equip pathogens, drug classes, and regional areas with detailed resistance pattern data, thus enabling both the clinician and the healthcare system to a more rapid response to the newly arisen threats.²⁴ Global burden analyses have confirmed that bacterial AMR is largely responsible for the great number of deaths, especially in low, and middle, income countries, which is a major reason for the implementation of surveillance data into clinical and public health interventions.¹⁵ Along with these trends, there are also considerable healthcare and economic costs linked to a longer hospital stay and treatment failure, thus the need for quicker and more effective responses to resistance is strengthened.²⁰ Artificial intelligence (AI) and machine learning, based techniques are gradually empowering clinical use of surveillance data by helping to pinpoint resistance mechanisms at an early stage and antimicrobial prescription support. Shen et al. (2022) deep, learning platform DeepARG for example has shown great ability in extracting resistance genes from sequencing data of clinical as well as environmental samples, hence it can identify potential resistance problems in due time before clinical dominance.⁹⁵ Comparable, Mycobacterium tuberculosis whole, genome sequencing data, driven machine, learning models have not only exhibited a high level of accuracy in detecting drug, resistant strains but also demonstrated the power of genomic information to facilitate almost instantaneous resistance pattern determination.⁹⁶ On top of that, predictive models built on electronic health records at the level of the healthcare system have been proven to be effective in predicting resistance both at patient and hospital scales, thus allowing more targeted antimicrobial use and avoiding antibiotic overuse.⁹⁷ In combination with current surveillance systems, such methods indicate a transition from resistance reporting retrospectively towards support systems that are anticipatory and clinically relevant.^24,95–97 Resistance patterns will still be influenced by environmental and contextual factors, however, their main significance for clinical decision, making is how they determine exposure and transmission rather than being a tool for long, term prediction. Epidemiological studies reveal links between higher outdoor temperatures and greater resistance in a number of bacterial species, while research on the environment indicates that pollutants such as heavy metals can co, select resistance genes.^{108, 110} The results of these studies point to the key role of environmental reservoirs in the persistence of resistance, and at the same time, they suggest that we should focus our efforts on surveillance methods that identify clinically relevant signals rather than when dealing with complex climate, driven changes.^108–110 Socioeconomic and health system factors additionally influence how quickly resistance can be detected and controlled. Resistance is still being fueled by weak laboratory capacity, unregulated antibiotic access, and limited diagnostic infrastructure in many places, even though surveillance and stewardship frameworks are available.^8,77,6 If there is no steady investment in diagnostics, surveillance integration, and antimicrobial stewardship, resistance will continue to undermine routine clinical care, including the treatment of common infections, surgical prophylaxis, and intensive care.^8,6 Therefore, the advancements in surveillance technology, AI, assisted analytics, and priority pathogen monitoring provide the greatest benefit when they are used to enhance immediate clinical decision, making rather than distant future prediction.^{15,24,62,77,6}
CONCLUSION

Scientists developed antibiotics in the past to kill harmful bacteria but their research led to the emergence of antimicrobial resistance as a major public health crisis which now constitutes the primary global health emergency of the twenty-first century. The review shows that AMR exists as a medical issue which extends beyond clinical prescribing because it represents an ecological and genetic and governance problem which links to human and animal and environmental systems. Microorganisms acquire resistance through genetic changes and gene acquisition and they spread through environmental and agricultural systems to create treatment failures which affect healthcare facilities throughout the world. The evidence shown here demonstrates that AMR now equals the deadliest infectious diseases while its actual impact remains hidden because of insufficient surveillance systems and diagnostic weaknesses with classification errors which particularly affect low- and middle-income countries. The decline of antibiotic effectiveness now endangers the essential elements of contemporary medical practice which includes common surgical procedures and cancer chemotherapy and neonatal medical treatment and intensive care services. The rising spread of resistance has extended beyond bacterial organisms to create a simultaneous crisis for antifungal drugs antiviral medicines and antiparasitic treatments because antimicrobial resistance develops as a natural response to medicinal treatment. Scientific understanding about the problem has advanced yet global responses to it continue to be disjointed. The three programs designated for stewardship together with surveillance systems and innovation systems face operational challenges because their implementation occurs separately which results from inadequate regulatory frameworks. The existing environmental contamination together with economic systems that create disincentives for antibiotic development and systems that enable antibiotic misuse, creates a situation which leads to operational challenges for stewardship programs together with surveillance systems and innovation systems. The existence of resistance reservoirs in wastewater systems along with soil and wildlife and constructed environments, explains why antibiotics resistance continues to exist even when clinical antibiotic usage drops. The review shows that effective AMR progress needs One Health governance as its framework for integrated management. The simultaneous implementation of three regulatory approaches is essential which requires antimicrobial use control for human and animal health plus environmental protection measures that prevent resistance spread and genomic and environmental surveillance systems that provide early detection and sustainable economic models for antibiotic development. Emerging technologies-such as AI-driven resistance prediction, precision antimicrobials, and genomic surveillance-offer powerful tools, but their impact will remain limited without strong political commitment and global cooperation. Antimicrobial resistance should not be understood as an unavoidable by, product of progress in medicine, but rather as a result of the aggregate decisions we make that can be controlled. If we fail to act decisively, this quiet pandemic will keep gaining ground without any interference, hence, what used to be infections that could be treated and cured will now take lives, and there will be more disparities in global health. On the other hand, antimicrobial effectiveness can be kept as a global public good through joint, forward, looking, and environmentally, aware measures, thus, the modern healthcare in the future will be safe.

ACKNOWLEDGEMENT

The authors would like to express their sincere gratitude to all faculty members, colleagues, and peers who provided valuable guidance, encouragement, and support during the preparation of this review manuscript. The authors also acknowledge the contributions of researchers and public health organizations worldwide whose published work and surveillance data formed the foundation of this review on antimicrobial resistance.

REFERENCES

1. Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med. 2022;14:eabo7793.
2. Iskandar K, Molinier L, Hallit S, et al. Drivers of antibiotic resistance transmission in low– and middle–income countries from a One Health perspective: a review. Antibiotics. 2020;9:372.
3. Zheng D, Yin G, Liu M, et al. A systematic review of antibiotics and antibiotic resistance genes in estuarine and coastal environments. Sci Total Environ. 2021;777:146009.
4. Wang X, Li J, Pan X. How micro–/nano–plastics influence the horizontal transfer of antibiotic resistance genes: a review. Sci Total Environ. 2024;944:173881.
5. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–187.
6. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Lancet Infect Dis. 2016;16:e353–e354.
7. Mendelson M, Sharland M, Mpundu M. Antibiotic resistance: calling time on the “silent pandemic”. JAC Antimicrob Resist. 2022;4:dlac016.
8. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353:874–875.
9. Laxminarayan R, Van Boeckel T, Frost I, et al. The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. Lancet Infect Dis. 2020;20:e51–e60.
10. Ya KZ, Win PT, Bielicki J, et al. Association between antimicrobial stewardship programs and antibiotic use globally: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2253806.
11. Wellington EM, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis. 2013;13:155–165.
12. Naghavi M, Vollset SE, Ikuta KS, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404:1199–1226.
13. Poudel AN, Zhu S, Cooper N, et al. The economic burden of antibiotic resistance: a systematic review and meta-analysis. PLoS One. 2023;18:e0285170.
14. Poku E, Cooper K, Cantrell A, et al. Systematic review of time lag between antibiotic use and rise of resistant pathogens among hospitalized adults in Europe. JAC Antimicrob Resist. 2023;5:dlad001.
15. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–655.
16. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56–66.
17. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163–1171.
18. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42:S82–S89.
19. Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20:973–980.
20. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–3910.
21. Mendelson M, Matsoso MP. The World Health Organization Global Action Plan for antimicrobial resistance. S Afr Med J. 2015;105:325.
22. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168–175.
23. Temesgen AB, Shiferaw SA. Antimicrobial multidrug resistance and mechanisms of action: an overview. Biomed Res Int. 2025;2025:8847267.
24. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2023. Geneva: World Health Organization; 2023.
25. Castañeda-Barba S, Top EM, Stalder T. Plasmids, a molecular cornerstone of antimicrobial resistance in the One Health era. Nat Rev Microbiol. 2024;22:18–32.
26. Partridge SR, Kwong SM, Firth N, et al. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31:e00088-17.
27. Pandey S, Doo H, Keum GB, et al. Antibiotic resistance in livestock, environment and humans: One Health perspective. J Anim Sci Technol. 2024;66:266–280.
28. Robinson TP, Bu DP, Carrique-Mas J, et al. Antibiotic resistance is the quintessential One Health issue. Trans R Soc Trop Med Hyg. 2016;110:377–380.
29. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2004;64:159–204.
30. Berendonk TU, Manaia CM, Merlin C, et al. Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol. 2015;13:310–317.
31. Rouvier F, Brunel JM, Pagès JM, et al. Efflux-mediated resistance in Enterobacteriaceae: recent advances and ongoing challenges to inhibit bacterial efflux pumps. Antibiotics. 2025;14:778.
32. Gillings MR. Integrons: past, present, and future. Microbiol Mol Biol Rev. 2014;78:257–277.
33. Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28:565–591.
34. Von Wintersdorff CJ, Penders J, Van Niekerk JM, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front Microbiol. 2016;7:173.
35. Lerminiaux NA, Cameron AD. Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol. 2019;65:34–44.
36. Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41:276-301.
37. Meradji S, Basher NS, Sassi A, et al. The role of water as a reservoir for antibiotic-resistant bacteria. Antibiotics. 2025;14:763.
38. Charani E, McKee M, Ahmad R, et al. Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research. Lancet Reg Health Eur. 2021;7:100161.
39. Klein EY, Milkowska-Shibata M, Tseng KK, et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21:107–115.
40. Karanika S, Paudel S, Grigoras C, et al. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother. 2016;60:4840-4852.
41. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27:520-531.
42. Calderón-Parra J, Muiño-Miguez A, Bendala-Estrada AD, et al. Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. PLoS One. 2021;16:e0251340.
43. Huttner BD, Catho G, Pano-Pardo JR, et al. COVID-19 and antimicrobial stewardship. Clin Microbiol Infect. 2020;26:808-810.
44. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:990-1001.
45. Mulchandani R, Wang Y, Gilbert M, et al. Global trends in antimicrobial use in food-producing animals: 2020 to 2030. PLoS Glob Public Health. 2023;3:e0001305.
46. McEwen SA, Collignon PJ. Antimicrobial resistance: a One Health perspective. Microbiol Spectr. 2018;6:ARBA-0009-2017.
47. Abate TA, Birhanu AG. Antibiotic use in livestock and environmental antibiotic resistance: a narrative review. Environ Health Insights. 2025;19:11786302251357775.
48. Mughini-Gras L, Dorado-García A, van Duijkeren E, et al. Attributable sources of community-acquired carriage of Escherichia coli containing ß-lactam antibiotic resistance genes: a population-based modelling study. Lancet Planet Health. 2019;3:e357–369.
49. Pires J, Kuenzli E, Kasraian S, et al. Transmission of resistant bacteria from animals to humans. Clin Microbiol Infect. 2022;28:684-692.
50. Van Boeckel TP, Glennon EE, Chen D, et al. Reducing antimicrobial use in food animals. Science. 2017;357:1350-1352.
51. Tang KL, Caffrey NP, Nóbrega DB, et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis. Lancet Planet Health. 2017;1:e316–327.
52. Van Boeckel TP, Pires J, Silvester R, et al. Global trends in antimicrobial resistance in animals in low-and middle-income countries. Science. 2019;365:eaaw1944.
53. Larsson DJ, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20:257-269.
54. Rizzo L, Manaia C, Merlin C, et al. Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: a review. Sci Total Environ. 2013;447:345-360.
55. Karkman A, Do TT, Walsh F, et al. Antibiotic-resistance genes in waste water. Trends Microbiol. 2018;26:220-228.
56. Imran M, Das KR, Naik MM. Co-selection of multi-antibiotic resistance in bacterial pathogens in metal and microplastic contaminated environments: an emerging health threat. Chemosphere. 2019;215:846-857.
57. Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10:1124.
58. Larsson DJ, Andremont A, Bengtsson-Palme J, et al. Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. Environ Int. 2018;117:132-138.
59. Bengtsson-Palme J, Kristiansson E, Larsson DJ. Environmental factors influencing the development and spread of antibiotic resistance. FEMS Microbiol Rev. 2018;42:fux053.
60. McCullough AR, Parekh S, Rathbone J, et al. A systematic review of the public's knowledge and beliefs about antibiotic resistance. J Antimicrob Chemother. 2016;71:27-33.
61. Ocan M, Obuku EA, Bwanga F, et al. Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. BMC Public Health. 2015;15:742.
62. Sakeena MH, Bennett AA, Jamshed S, et al. Investigating knowledge regarding antibiotics and antimicrobial resistance among pharmacy students in Sri Lankan universities. BMC Infect Dis. 2018;18:209.
63. Sumpradit N, Wongkongkathep S, Poonpolsup S, et al. New chapter in tackling antimicrobial resistance in Thailand. BMJ. 2017;358:j3415.
64. Charani E, Mendelson M, Pallett SJ, et al. An analysis of existing national action plans for antimicrobial resistance - gaps and opportunities in strategies optimising antibiotic use in human populations. Lancet Glob Health. 2023;11:e466–74.
65. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–18.
66. Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.
67. Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557–71.
68. Lockhart SR. Candida auris and multidrug resistance: defining the new normal. Fungal Genet Biol. 2019;131:103243.
69. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16:603–16.
70. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18:346–55.
71. Thorlund K, Awad T, Boivin G, et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011;11:134.
72. Hotez PJ, Pecoul B. Manifesto for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis. 2010;4:e718.
73. Aranega-Bou P, George RP, Verlander NQ, et al. Carbapenem-resistant Enterobacteriaceae dispersal from sinks is linked to drain position and drainage rates in a laboratory model system. J Hosp Infect. 2019;102:63–69.
74. Mahnert A, Moissl-Eichinger C, Zojer M, et al. Man-made microbial resistances in built environments. Nat Commun. 2019;10:968.
75. Hayward C, Ross KE, Brown MH, et al. Drinking water plumbing systems are a hot spot for antimicrobial-resistant pathogens. J Hosp Infect. 2025;159:62–70.
76. Carroll D, Wang J, Fanning S, et al. Antimicrobial resistance in wildlife: implications for public health. Zoonoses Public Health. 2015;62:534–42.
77. Collignon P, Beggs JJ, Walsh TR, et al. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet Health. 2018;2:e398–405.
78. Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis. 2018;66:1290–97.
79. Cassini A, Plachouras D, Monnet DL. Attributable deaths caused by infections with antibiotic-resistant bacteria in France - Authors' reply. Lancet Infect Dis. 2019;19:129–30.
80. De Oliveira DM, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33:e00181–19.
81. Martinez Arroyo M, Hernandez Gonzalez E, Guedes Vidal LY. Patrones de resistencia antimicrobiana en uropatógenos de pacientes hospitalizados. Salud Cienc. 2012;18:732–36.
82. Xu E, Perez-Torres D, Fragkou PC, et al. Nosocomial pneumonia in the era of multidrug-resistance: updates in diagnosis and management. Microorganisms. 2021;9:534.
83. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063–1143.
84. Li G, Bielicki JA, Ahmed AN, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105:26–31.
85. Miethke M, Pieroni M, Weber T, et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 2021;5:726–49.
86. Butler MS, Gigante V, Sati H, et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022;66:e01991–21.
87. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
88. Pirnay JP, Verbeken G, Ceyssens PJ, et al. The magistral phage. Viruses. 2018;10:64.
89. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730–33.
90. Yosef I, Manor M, Kiro R, et al. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci USA. 2015;112:7267–72.
91. Pursey E, Sunderhauf D, Gaze WH, et al. CRISPR-Cas antimicrobials: challenges and future prospects. PLoS Pathog. 2018;14:e1006990.
92. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227–49.
93. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688–702.
94. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56.
95. Arango-Argoty G, Garner E, Pruden A, et al. DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. Microbiome. 2018;6:23.
96. Yang Y, Niehaus KE, Walker TM, et al. Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics. 2018;34:1666–71.
97. Sakagianni A, Koufopoulou C, Feretzakis G, Kalles D, Verykios VS, Myrianthefs P, et al. Using machine learning to predict antimicrobial resistance: a literature review. Antibiotics (Basel). 2023;12:452.
98. Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: the need for a One Health - One Europe - One World framework. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2016.
99. Huttner B, Saam M, Moja L, et al. How to improve antibiotic awareness campaigns: findings of a WHO global survey. BMJ Glob Health. 2019;4:e001239.
100. Quainoo S, Coolen JP, van Hijum SA, et al. Whole-genome sequencing of bacterial pathogens: the future of nosocomial outbreak analysis. Clin Microbiol Rev. 2017;30:1015–63.
101. Towse A, Hoyle CK, Goodall J, et al. Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy. 2017;121:1025–30.
102. Hernando-Amado S, Coque TM, Baquero F, et al. Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat Microbiol. 2019;4:1432–42.
103. World Health Organization. Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. Geneva: World Health Organization; 2021.
104. Food and Agriculture Organization, United Nations Environment Programme, World Health Organization, World Organisation for Animal Health. One Health Joint Plan of Action (2022–2026): working together for the health of humans, animals, plants and the environment. Rome: FAO; 2022.
105. Munk P, Knudsen BE, Lukjancenko O, et al. Abundance and diversity of the faecal resistome in slaughter pigs and broilers in nine European countries. Nat Microbiol. 2018;3:898–908.
106. Speksnijder DC, Mevius DJ, Bruschke CJ, et al. Reduction of veterinary antimicrobial use in the Netherlands: the Dutch success model. Zoonoses Public Health. 2015;62:79–87.
107. Public Health Agency of Sweden, National Veterinary Institute. Swedres-Svarm 2021: sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala: Public Health Agency of Sweden; 2021.
108. MacFadden DR, McGough SF, Fisman D, et al. Antibiotic resistance increases with local temperature. Nat Clim Change. 2018;8:510–14.
109. Baker-Austin C, Wright MS, Stepanauskas R, et al. Major uncertainties and future research opportunities in metal-antibiotic co-selection. Trends Microbiol. 2006;14:176–82.
110. Ashbolt NJ, Amezquita A, Backhaus T, et al. Human health risk assessment for environmental development and transfer of antibiotic resistance. Environ Health Perspect. 2013;121:993–1001.